Medication evidence profile
Reboxetine
Clinical overview
Reboxetine has public medication-list entries in Yamada-ABS 2023, Swe-ABS 2023, and GABS 2018. These are 3 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | Not listed |
| Yamada-ABS | 2 |
| BAAS | Not listed |
| Swe-ABS | 0 |
| GABS | 0 |
| KABS | Not listed |
| CALS | Not listed |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
3 of 7 public source versions contain an explicit medication-list entry for Reboxetine.
The recorded values differ across the source rows for Reboxetine. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.
Swe-ABS 2023 and GABS 2018 explicitly record zero. Those recorded zeros remain different from a missing entry.
Source labels and provenance · 3 observations
- Yamada Pharmacological Anticholinergic Burden Scale 2023
Source label: Reboxetine. Published value: 2.
Source version: YAMADA-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
Observation: YAMADA_ABS_2023_R0036; rating state: published_rating. - Swedish Anticholinergic Burden Scale 2023
Source label: Reboxetine. Published value: 0.
Source version: SWE-ABS-2023
Source location: 12877_2023_4225_MOESM1_ESM.docx ST3 row 206
Observation: SWE_ABS_2023_R0331; rating state: published_zero. - German Anticholinergic Burden Score 2018
Source label: Reboxetine. Published value: 0.
Source version: GABS-2018
Source location: 12877_2018_929_MOESM1_ESM.docx Table S3 row 291
Observation: GABS_2018_R0441; rating state: published_zero.
Dose, route, and formulation notes
Distinct v3 concept retained conservatively; do not collapse by substring or class similarity.
What this page does not establish
- No medication-list entry is available here from JARS 2025, BAAS 2019, KABS 2020 open validation supplement, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- Use source-specific route/formulation where provided.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
- Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
- Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Reboxetine
Ask about this medication